Incretin Atlas › Molecules › Aleniglipron
Aleniglipron
GLP-1 (small molecule) · oral · Structure Therapeutics
Summary
- Also known as
- GSBR-1290, Structure Therapeutics
- Mechanism
- GLP-1 (small molecule)
- Route
- oral
- Company
- Structure Therapeutics
- Highest development stage
- phase 3
- Status (as of data cut)
- Two pivotal phase 3 trials (obesity; obesity with or without T2D) recruiting since Jul 2026; phase 2b ACCESS reported 2025 verify
- Next milestone
- Phase 3 results (primary completion Sep 2028)
Sources for the status
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity. ClinicalTrials.gov identifier NCT07654361. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07654361
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2). ClinicalTrials.gov identifier NCT07654374. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07654374
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACCESS (phase 2b) | aleniglipron 45 mg | obesity | 36 | 45 | −9.0 % vs −0.8 % Δ −8.2 pp | −8.8 % vs −1.0 % Δ −7.8 pp | −0.3 vs +0.0 | 13.3 vs 5.4 | 26.7 vs 25.0 | 71.1 vs 21.4 | 40.0 vs 5.4 | 2.2 vs 5.4 | −7.9 vs −1.5 | verified |
| ACCESS (phase 2b) | aleniglipron 90 mg | obesity | 36 | 65 | −10.7 % vs −0.8 % Δ −9.9 pp | −10.2 % vs −1.0 % Δ −9.2 pp | −0.3 vs +0.0 | 7.7 vs 5.4 | 24.6 vs 25.0 | 67.7 vs 21.4 | 44.6 vs 5.4 | 0.0 vs 5.4 | −8.9 vs −1.5 | verified |
| ACCESS (phase 2b) | aleniglipron 120 mg | obesity | 36 | 64 | −12.1 % vs −0.8 % Δ −11.3 pp | −11.4 % vs −1.0 % Δ −10.4 pp | −0.4 vs +0.0 | 11.1 vs 5.4 | 21.9 vs 25.0 | 65.1 vs 21.4 | 31.7 vs 5.4 | 6.3 vs 5.4 | −9.0 vs −1.5 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- aleniglipron 45 mg: Oral, once daily; titration from 5 mg every 4 weeks. Pooled placebo. Treatment-policy column = the paper's «treatment regimen estimand».
- aleniglipron 90 mg: Oral, once daily; titration from 5 mg every 4 weeks. Pooled placebo. Treatment-policy column = the paper's «treatment regimen estimand».
- aleniglipron 120 mg: Oral, once daily; titration from 5 mg every 4 weeks. Pooled placebo. Treatment-policy column = the paper's «treatment regimen estimand».
Verbatim quotes from the source (27)
- aleniglipron 45 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
- aleniglipron 45 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
- aleniglipron 45 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
- aleniglipron 45 mg · disc_any · Fig. 1 CONSORT
33 (73.3%) Completed treatment (week 36) 12 (26.7%) Discontinued study treatment 6 (13.3%) Adverse event
- aleniglipron 45 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
- aleniglipron 45 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
- aleniglipron 45 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
- aleniglipron 45 mg · hba1c · Extended Data Table 5
Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
- aleniglipron 45 mg · sbp · Extended Data Table 5
Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
- aleniglipron 90 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
- aleniglipron 90 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
- aleniglipron 90 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
- aleniglipron 90 mg · disc_any · Fig. 1 CONSORT
16 (24.6%) Discontinued study treatment 5 (7.7%) Adverse event
- aleniglipron 90 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
- aleniglipron 90 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
- aleniglipron 90 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
- aleniglipron 90 mg · hba1c · Extended Data Table 5
Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
- aleniglipron 90 mg · sbp · Extended Data Table 5
Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
- aleniglipron 120 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
- aleniglipron 120 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
- aleniglipron 120 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
- aleniglipron 120 mg · disc_any · Fig. 1 CONSORT
14 (21.9%) Discontinued study treatment 7 (10.9%) Adverse event
- aleniglipron 120 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
- aleniglipron 120 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
- aleniglipron 120 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
- aleniglipron 120 mg · hba1c · Extended Data Table 5
Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
- aleniglipron 120 mg · sbp · Extended Data Table 5
Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
Registered trials (2)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| ACCOMPLISH-1 Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) | Obesity | Phase 3 | recruiting | 2026-07 → 2028-09 | 3600 | recruiting | NCT07654361 |
| ACCOMPLISH-2 A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) | Obesity | Phase 3 | recruiting | 2026-07 → 2028-09 | 1100 | recruiting | NCT07654374 |
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Aleniglipron. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/aleniglipron/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.